Timing of Antidiabetic Medication Initiation and Risk of Cardiovascular Events and Mortality
JAMA Network Open · 2026
DOI: 10.1001/jamanetworkopen.2026.19362 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Network Open, 2026. Verfasst von Hwa Yeon Ko und 13 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Sungkyunkwan University, Suwon, South Korea. Hauptthemen laut MEDLINE: Hypoglycemic Agents, Diabetes Mellitus, Type 2, Cardiovascular Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Among individuals who meet the diagnostic threshold for type 2 diabetes (T2D), timely initiation of antidiabetic medication (ADM) is essential for lowering long-term cardiovascular risk.
Objective
To estimate the association between ADM initiation timing—specifically within 3, 6, or 12 months—and the risk of major adverse cardiovascular events (MACE) and all-cause mortality among individuals newly meeting diagnostic criteria for T2D. Design, Setting, and Participants This cohort study used target trial emulation to analyze health screening data linked to health insurance claims in Korea (2013-2022) using a clone-censor-weight approach. Participants were adults with newly detected glycated hemoglobin (HbA 1c ) of 6.5% or greater or fasting plasma glucose of 126 mg/dL or greater. Data analysis was conducted from January to August 2025. Exposures Eligible participants were cloned into 4 treatment strategies: ADM initiation within 3, 6, or 12 months or no initiation within 12 months (strategy 1, 2, 3, and control, respectively). Main outcomes and Measures Five-year absolute risk difference (RD) and risk ratio (RR) of 3-point MACE (stroke, myocardial infarction, and all-cause mortality) and all-cause mortality were estimated using Kaplan-Meier survival probabilities along with 95% CIs from 1000-sample nonparametric bootstrapping.
Results
A total of 23 452 eligible participants (mean [SD] age, 48.2 [11.1] years; 5790 [24.7%] female; mean [SD] HbA 1c , 6.9% [1.1%]) were cloned into 4 treatment strategies. Earlier ADM initiation compared with the control showed progressively lower point estimates for 3-point MACE (RR, 0.32; 95% CI, 0.15 to 1.11 for strategy 1; RR, 0.65; 95% CI, 0.41 to 1.29 for strategy 2; RR, 0.93; 95% CI, 0.70 to 1.41 for strategy 3), though it did not achieve statistical significance. Corresponding RDs were −0.97% (95% CI, −1.26% to 0.14%), −0.49% (−0.84% to 0.40%), and −0.10% (−0.44% to 0.57%), respectively. ADM initiation within 3 months yielded significant risk reduction for all-cause mortality compared with the control in both relative (RR, 0.31; 95% CI, 0.10-0.98) and absolute (RD, −0.40%; 95% CI, −0.57% to −0.01%) scales. Conclusions and Relevance In this cohort study, earlier ADM initiation following the diagnostic threshold for T2D showed a lower risk of mortality, suggesting a potential cardiovascular benefit of early glycemic control; however, given the low event counts and the observational nature of the study, further evaluation in larger studies is warranted before definitive conclusions can be drawn.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Sungkyunkwan University, Suwon, South Korea.
- Department of Biohealth Regulatory Science, Sungkyunkwan University, Suwon, South Korea.
- Department of Clinical Research Design and Evaluation, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, South Korea.
- Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
- Gerald Bronfman Department of Oncology, Faculty of Medicine and Health Sciences, McGill University.
- College of Pharmacy, Chonnam National University, Gwangju, South Korea.
Zitieren
APA
Ko, H. Y., Shin, J. Y., Jung, K., Bea, S., Hong, B., Noh, Y., Bae, J. H., Kwak, S. H., Cho, Y. M., Lim, G. Y., Ahn, J., Ryu, S., Kim, J. H., & Chang, Y. (2026). Timing of Antidiabetic Medication Initiation and Risk of Cardiovascular Events and Mortality. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2026.19362
Vancouver
Ko HY, Shin JY, Jung K, Bea S, Hong B, Noh Y, et al. Timing of Antidiabetic Medication Initiation and Risk of Cardiovascular Events and Mortality. JAMA Network Open. 2026. doi:10.1001/jamanetworkopen.2026.19362
BibTeX
@article{Ko2026,
author = {Ko, Hwa Yeon and Shin, Ju-Young and Jung, Kyungyeon and Bea, Sungho and Hong, Bin and Noh, Yunha and Bae, Jae Hyun and Kwak, Soo Heon and Cho, Young Min and Lim, Ga-Young and Ahn, Jiin and Ryu, Seungho and Kim, Ju Hwan and Chang, Yoosoo},
title = {Timing of Antidiabetic Medication Initiation and Risk of Cardiovascular Events and Mortality},
journal = {JAMA Network Open},
year = {2026},
doi = {10.1001/jamanetworkopen.2026.19362}
}
EUVIMED